Medifast (MED) Tops Q2 EPS by 44c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts MED Hot Sheet
Price: $10.62 -3.63%
EPS Growth %: -295.5%
Financial Fact:
Selling, general, and administration: 43.21M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -295.5%
Financial Fact:
Selling, general, and administration: 43.21M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Medifast (NYSE: MED) reported Q2 EPS of $0.22, $0.44 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $105.6 million versus the consensus estimate of $96.1 million.
GUIDANCE:
Medifast sees Q3 2025 EPS of ($0.60)-$0.00, versus the consensus of ($0.30). Medifast sees Q3 2025 revenue of $70-90 million, versus the consensus of $93.8 million.
For earnings history and earnings-related data on Medifast (MED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Enanta Pharma loses appeal in Pfizer Paxlovid patent case
- Cerebras Systems posts 94% revenue jump, announces OpenAI deal
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
